Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata
NCT ID: NCT03976622
Last Updated: 2019-06-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
450 participants
OBSERVATIONAL
2019-06-03
2023-06-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Deciphering the Vitiligo Transcriptomic Signature Between Repigmented and Non Repigmented Lesions
NCT05927272
Translational Assessment of Vitiligo According to Body Locations
NCT06068218
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
NCT06599411
A Pilot Cohort Study of Risk Factors and Novel Methods of Skin Lesion Assessments in Adults With Atopic Dermatitis, Alopecia Areata, Psoriasis or Vitiligo
NCT06319781
Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo
NCT03249064
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
vitiligo
Patients aged 18 to 75 years with non-segmental vitiligo;
Blood samples
Blood samples: serum and PBMC
Skin biopsies
These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.
psoriasis
Patients aged 18 to 75 years with plaque psoriasis;
Blood samples
Blood samples: serum and PBMC
Skin biopsies
These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.
atopic dermatitis
Patients aged 18 to 75 years with atopic dermatitis;
Blood samples
Blood samples: serum and PBMC
Skin biopsies
These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.
alopecia areata
Patients aged 18 to 75 years with alopecia areata sclerosis;
Blood samples
Blood samples: serum and PBMC
Skin biopsies
These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood samples
Blood samples: serum and PBMC
Skin biopsies
These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with non-segmental vitiligo;
* Patients with plaque psoriasis;
* Patients with atopic dermatitis;
* Patients with alopecia areata sclerosis;
* written consent, free, informed and signed by the patient and the investigator (before any examination required by the study);
* Subject affiliated or beneficiary of a social security system.
Exclusion Criteria
* Patients under local treatment (topical corticosteroid-Calcineurin inhibitor) for less than two weeks.
* Patients on therapy, systemic treatments: acitretin, methotrexate, cyclosporine, Apremilast, infliximab, adalimumab, etanercept, ustekinumab, secukinumab, ixekizumab, dupilumab) for less than 4 weeks.
* Pregnant or breastfeeding women
* Patient (e) under guardianship
* Patient (e) Non-affiliated (e) a social protection
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Bordeaux
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julien SENESCHAL, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Bordeaux
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service de Dermatologie - Hôpital Saint-André
Bordeaux, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHUBX 2017/55
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.